Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

Conditions:   Cutaneous Melanoma;   Non-small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Urothelial Carcinoma;   Renal Cell Carcinoma Interventions:   Biological: GEN-009 Adjuvanted Vaccine;   Drug: Nivolumab Sponsor:   Genocea Biosciences, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials